ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 16,800 shares, an increase of 100.0% from the September 30th total of 8,400 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 1.4 days.
ProShares Ultra Nasdaq Biotechnology Stock Up 0.2 %
NASDAQ:BIB traded up $0.12 during trading hours on Friday, reaching $61.85. 4,349 shares of the company’s stock were exchanged, compared to its average volume of 24,261. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $40.10 and a 1-year high of $69.56. The company has a 50-day moving average of $64.66 and a 200 day moving average of $60.63.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The business also recently disclosed a dividend, which was paid on Wednesday, October 2nd. Shareholders of record on Wednesday, September 25th were given a dividend of $0.1528 per share. This is a boost from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.04. The ex-dividend date was Wednesday, September 25th.
Institutional Inflows and Outflows
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
See Also
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Quiet Period Expirations Explained
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the Australian Securities Exchange (ASX)
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Does Downgrade Mean in Investing?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.